Today: 9 June 2026
Morgan Stanley stock rebounds after Thursday slide as CPI cools; Fed minutes, Basel rules loom
14 February 2026
2 mins read

Morgan Stanley stock rebounds after Thursday slide as CPI cools; Fed minutes, Basel rules loom

New York, Feb 14, 2026, 16:03 EST — Market is done for the day

  • Morgan Stanley bounced back Friday, climbing 1.8% to $171.15, recouping some ground after tumbling 4.9% the previous day.
  • U.S. inflation numbers cooled, taking some heat off rate expectations. Still, investors are bracing for potential new swings.
  • With the week cut short by a holiday, traders are eyeing the release of Fed minutes on Feb. 18, while talk around upcoming big-bank capital rules remains in focus.

Shares of Morgan Stanley (MS) finished Friday 1.8% higher at $171.15, clawing back some losses from the previous session’s drop. After the bell, the stock changed hands at $171.40.

Why does it matter now? Investors are assessing whether the fresh “AI disruption” trade stays confined to software—or spills over into segments like wealth management, right in Morgan Stanley’s wheelhouse. “It’s all this whack-a-mole game of trying to figure out what AI is going to destroy next,” said Art Hogan, chief market strategist at B Riley Wealth, in a week-ahead note on markets. Reuters

Stocks steadied and Treasury yields drifted lower Friday, after softer-than-forecast January consumer price numbers. That data bump was enough for traders to price in a 52.3% chance of a 25-basis-point rate cut in June, up from 48.9%, CME’s FedWatch shows. “Large cap tech stocks continue to be an anchor on the market,” said Michael James, managing director at Rosenblatt Securities. James also noted the coming three-day weekend gave investors an excuse to lighten positions. Reuters

Wall Street tumbled the previous day, tech names under heavy pressure as investors fled to defensive plays. The mood grew more uneasy, with questions swirling about which sectors could actually get squeezed by the latest AI innovations—and what the price tag looks like to stay competitive. “We see this as a ‘prove it’ year for AI,” said Jack Herr, primary investment analyst at GuideStone Funds. Reuters

At Morgan Stanley, shifting rate bets and market turbulence feed straight into trading volumes, deal talk, and the wealth management desk’s client traffic. Busy markets? That’s a boost. When clients freeze up, though, the downside hits fast.

Regulation remains a sticking point. U.S. bank regulators are edging nearer to rolling out a new draft of the so-called “Basel endgame” rules, global standards dictating how major banks like JPMorgan, Goldman Sachs, and Morgan Stanley calculate risk and maintain capital buffers. According to Reuters, the FDIC and OCC have already sent their proposals to the White House budget office for review. There was no sign of a Federal Reserve proposal posted as of this day. Reuters

Morgan Stanley on Friday announced it’s declaring regular dividends for multiple preferred stock series, with record dates set for Feb. 27 and March 31.

The risk, though, is clear enough. Should the capital rewrite come in stricter than investors are betting on, banks could be forced to hold extra buffers for trading and lending operations, squeezing the space for buybacks. And if the sector volatility keeps leaking into wealth businesses, mood could sour quickly.

No trading in U.S. stocks Monday—Washington’s Birthday shuttered the equity markets. Doors open again Tuesday.

The big one coming up: Investors will pick through the Federal Reserve’s Jan. 27–28 meeting minutes, due out Feb. 18 at 2 p.m. ET, hunting for clues on any change in policymakers’ stance on rate cuts.

Stock Market Today

  • Investment Fund Outperforms with Focus on Affordable AI Stocks
    June 9, 2026, 10:50 AM EDT. A diversified investment fund specializing in cheap AI stocks has outperformed the broader market, demonstrating the benefits of a closed-end fund structure. These funds typically have a fixed number of shares, allowing managers more flexibility to focus on long-term gains rather than daily redemptions. The strategy prioritizes exposure to undervalued artificial intelligence companies, capturing growth potential while managing risk. This performance underscores the appeal of integrating AI sector opportunities within a closed-end investment vehicle for investors seeking market-beating returns.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus
Previous Story

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus

DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next
Next Story

DraftKings stock price tumbles after 2026 outlook miss; what DKNG traders watch next

Go toTop